Overview

Efficacy and Safety Study of Vicagrel in Patients With Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI)

Status:
RECRUITING

Trial end date:
2026-12-30

Target enrollment:

Participant gender:

Summary

This is a multi-center, randomized, double-blind, double-dummy, parallel-controled, phase III trial, aiming to evaluate the effectiveness and safety of long-term continuous administration of Vicagrel capsules in ACS patients undergoing PCI.

Phase:

PHASE3

Details

Lead Sponsor:

Jiangsu vcare pharmaceutical technology co., LTD

Treatments:

Clopidogrel
methyl 2-(2-acetoxy-6,7-dihydrothieno(3,2-c)pyridin-5(4H)-yl)-2-(2-chlorophenyl)acetate